Companies: 10,795·Total market cap: $144.5T
XBiotech Inc.

XBiotech Inc.

XBITNASDAQHealthcare● Active
$2.37
+$0.00(+0.00%)
Market Cap$72255922
P/E Ratio—
52W High$3.61
52W Low$2.09
ForecastMarket CapPE Ratio

XBiotech Inc.（XBIT）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

xbit · 股价预测 · 3 位分析师（近3月）· FMP · 更新于 2026年6月9日

分析师评级与共识

基于过去 3 个月内 3 位华尔街分析师

SellBuy

Buy

3 位分析师

共识

评级分布

Strong Buy
0
Buy
3
Hold
0
Sell
0
Strong Sell
0
合计: 3 · 买入占比: 100.0%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $2.37

XBiotech Inc.（XBIT）的分析师共识为 Buy，基于过去 3 个月内 3 位华尔街分析师的评级。XBIT 的 12 个月平均目标价为 $0.00，相对当前价 $2.37 代表 +0.0% 的潜在上行空间。

短期股价预测

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-10$2.34↓ 1.18%

1-day model range: $2.34–$2.35. Peak: $2.35 (-1.18%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$2-32.8%
2028$1-43.8%
2029$1-48.5%
2030$1-50.6%
2031—-51.6%
Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

0%7%93%
0Buy
1Neutral
13Sell
RSI (14)46.1Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · XBIT · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$2.38SELL
MA 10$2.40SELL
MA 20$2.42SELL
MA 50$2.44SELL
MA 100$2.42SELL
MA 200$2.51SELL
Current $XBIT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$2.38SELL
EMA 10$2.40SELL
EMA 20$2.42SELL
EMA 50$2.43SELL
EMA 100$2.45SELL
EMA 200$2.63SELL
Current $XBIT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Piper Sandler2020-04-07
Maintains
Overweight→Overweight
PiperJaffray2019-12-11
Maintains
Overweight→Overweight
Piper Sandler2019-12-11
Maintains
Overweight→Overweight
Piper Sandler2019-06-14
Maintains
Overweight→Overweight
Piper Jaffray2019-06-14
Maintains
Overweight→Overweight

Wall Street analysts have recently issued updated ratings on XBiotech Inc. (XBIT) stock. Of the recent 5 rating actions, 0 were upgrades and 0 were downgrades. 3 analysts currently cover XBIT.

分析师推荐趋势

Buy ratings2 → 1↓ 1
Hold ratings0 → 0
Sell ratings0 → 0

XBIT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$28M

↓ 81.3% YoY

Revenue Next Year

$28M

↑ 0.0% YoY

EPS This Year

$0.19

EPS Next Year

$0.13

↓ 31.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast XBIT EPS of $0.19 for the current fiscal year, based on estimates from 1 analysts. The XBIT revenue forecast is $28M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

XBIT 股价预测由两类独立数据源支撑：来自 3 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。XBIT 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Buy。

XBIT 的短期预测（明日）为 $2.34（-1.18%）。 XBIT 对 2027 年的股价预测均值为 $2。 XBIT 对 2030 年的预测区间为 $1–$1。

XBiotech Inc. 在 NASDAQ 上市，代码 XBIT。XBIT 在 2027 年的整体展望偏积极，在覆盖分析师中约 100% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

XBIT 预测 · 8 个问题

根据 3 位华尔街分析师，XBIT 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $2.37，隐含约 +0.0% 的上行空间。

XBIT 目标价XBIT 分析师目标价XBIT 12个月目标价目标价 XBIT

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.